The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment

In this episode of Denatured, you'll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech's next big frontier.

Host

 

Jennifer C. Smith-Parker, Director of Insights, BioSpace

 

Guests

 

Marc Hedrick, President & CEO, Plus Therapeutics

 

Philip Kantoff, Co-founder & CEO, Convergent Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.